Toboroz
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151· 3. fázis· AstraZeneca· Forrás
Toboroz
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· 3. fázis· AstraZeneca· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Toboroz
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· 3. fázis· Arcus Biosciences, Inc.· Forrás
Contact: Medical Director
Toboroz
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338· 2. fázis· AstraZeneca· Forrás
Toboroz
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577· 2. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038· 1/2. fázis· AstraZeneca· Forrás
Toboroz
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595· 3. fázis· AstraZeneca· Forrás
Toboroz
Observational Study Protocol: LIVER-R
NCT06252753· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642· 1. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772· 3. fázis· Acerta Pharma BV· Forrás
Fut, nem toboroz
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
NCT04068610· 1/2. fázis· MedImmune LLC· Forrás
Fut, nem toboroz
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261· 3. fázis· Acerta Pharma BV· Forrás
Fut, nem toboroz
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840· 3. fázis· Acerta Pharma BV· Forrás
Fut, nem toboroz
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
NCT01843374· 2. fázis· MedImmune LLC· Forrás